NCT05564338View on ClinicalTrials.gov

Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2023

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2028

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Sitravatinib

Administered orally

DRUG

Tislelizumab

Administered intravenously

DRUG

sitravatinib-matching placebo

administered orally

DRUG

tislelizumab-matching placebo

administered intravenously

Sponsors

Lead Sponsor

BeiGene
All Listed Sponsors
lead

BeiGene

INDUSTRY

NCT05564338 - Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter